Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ascentage Pharma Group International ( (HK:6855) ) has shared an update.
Ascentage Pharma presented results from five preclinical studies at the 2025 AACR Annual Meeting, showcasing the synergistic effects of their drug candidates olverembatinib and lisaftoclax. The studies demonstrated that the combination of these drugs effectively overcomes resistance to venetoclax in acute myeloid leukemia models, suggesting a promising new therapeutic strategy. Additionally, the combination showed antitumor effects in T-cell acute lymphoblastic leukemia models, highlighting its potential impact on treatment options for high-risk hematologic cancers.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing innovative therapies for cancer, chronic hepatitis B, and age-related diseases. The company specializes in creating novel drug candidates, including tyrosine kinase inhibitors and Bcl-2 inhibitors, targeting various hematologic malignancies and solid tumors.
YTD Price Performance: 13.31%
Average Trading Volume: 4,222,904
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.78B
For an in-depth examination of 6855 stock, go to TipRanks’ Stock Analysis page.